The terminal complement inhibitor Eculizumab (anti-C5) has been used as rescue therapy of AIHA in a patient with Waldenström macroglobulinemia (72) and in a patient with chronic myelomonocytic leukemia (CMML) (73). This evidence concerns the gene C5 and chronic myelomonocytic leukemia.